In 2023, PDC-CRO, a top clinical research organisation, executed a direct-to-biotech strategy. This strategy bolstered its status as a comprehensive partner for biotech firms in the Gulf and Levant regions. Saudi Arabia, with its growing healthcare sector, benefited significantly from this strategy. The country’s regulatory environment, commercial influence, and large patient population underpin its increasing influence. This article summarises a recent interview with PDC-CRO’s CEO, Mohamed Mostafa, posted on Pharma Boardroom, providing insightful perspectives on the future of clinical trials in Saudi Arabia.
PDC-CRO’s success in 2023 can be attributed to a strategic focus on a direct-to-biotech strategy, which differs from traditional approaches that heavily rely on subcontracting with major CROs. This approach involves providing comprehensive support to biotech firms in the Gulf and Levant regions including the UAE, Jordan, and Lebanon. This investment has positioned PDC-CRO well to compete in the market and effectively serve its biotech partners. They have adopted a model where 50% of revenue comes from worldwide CRO collaborations and 50% from biotech direct engagement.
Saudi Arabia holds significant importance in the region and the global healthcare industry. The country’s regulatory framework has evolved remarkably. Moreover, ensuring a robust system for clinical trials and research ethics, outperforming Egypt and Algeria. Furthermore, the mandate for Big Pharma to establish regional offices in Saudi Arabia reflects the growing commercial significance of the market. Clinical trials are ideal in Saudi Arabia due to its size and commercial power. Novartis, MSD, and Pfizer have acknowledged this and adjusted their strategies.
Despite the advancements, conducting clinical trials in Saudi Arabia comes with its own set of challenges. These include ensuring efficient trial management, motivating investigators, and logistical coordination. However, the establishment of dedicated clinical trial units within hospitals and the introduction of site management organisations (SMOs) has facilitated trial operations, making participation more attractive to investigators.
Looking ahead, PDC-CRO aims to engage in phase one clinical trials in Saudi Arabia. They are committed to provide full clinical development from the outset. The company also plans to introduce managed access programs in Saudi Arabia through its sister company, aiming to bring products developed by global biotechs to patients in need.
While financial investment from major players like Elanco exists, there is often a lack of strategic alignment and operational presence in the region. This disconnect between financial investment and operational strategy highlights a crucial gap that needs to be addressed. To fully capitalise on Saudi Arabia’s potential as a hub for clinical trials, there needs to be alignment between scientific, strategic, and investment objectives. Companies must develop comprehensive strategies that consider the unique opportunities and challenges present in the region.
In conclusion, PDC-CRO steadfastly commits to discovering effective patient treatments across the region. The company views clinical trials as a viable enhancement to treatment options and works tirelessly to progress the clinical trial landscape. This showcases the country’s potential. Through the alignment of financial investment and operational strategy, PDC-CRO forges a future where Saudi Arabia enjoys more accessible and effective healthcare.
🚀 Is the non-opioid pain management market on the verge of a strategic shift?
Viatris’ MR-107A-02 shows 73% opioid-free recovery in herniorrhaphy, strong Phase 3 efficacy, and placebo-comparable safety.
With a $45B market at stake, the implications for commercial strategy and payer positioning are significant.
Read our full breakdown—market dynamics, clinical data, and the transformative potential of MR-107A-02.
#SyenzaNews #pharmaceuticals #HealthcareInnovation
🔍 What if we could transform the treatment landscape for chronic Hepatitis Delta Virus (HDV)?
Recent findings from Gilead’s Phase 3 MYR301 study reveal that bulevirtide therapy not only achieves remarkable virologic control during treatment but also sustains that control after therapy cessation for many patients. With a striking 90% of patients remaining undetectable post-treatment, this could signify a major breakthrough in HDV management.
Learn more about how this could reshape patient outcomes and health economics? See full article for all the insights!
#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess
💡 Is prevention really saving us money in healthcare?
In their thought-provoking article, “Can Prevention Save Money?”, Baicker and Chandra challenge the prevailing notion that preventive health measures always reduce costs. They argue that while prevention can enhance health outcomes, it often leads to increased spending upfront, and the key lies in evaluating these programs based on their cost-effectiveness instead of expecting them to save money outright.
Curious about the real financial implications of preventive care? Dive into the full analysis to uncover the nuances!
#SyenzaNews #HealthEconomics #costeffectiveness #healthcarepolicy
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
